Investment Thesis
Agios is a pre-profitability pharmaceutical company with positive revenue growth (48% YoY) but massive operating losses (-$110M on $20.7M revenue) and a tight cash runway of approximately 1 year at current burn rates. While the balance sheet is structurally sound with minimal debt and $1.1B equity, negative operating cash flow of -$118.9M indicates the company is unsustainable at its current trajectory without significant revenue acceleration or cost reduction.
Strengths
- Strong balance sheet with $1.1B stockholders equity and zero long-term debt
- Excellent liquidity position with 14.19x current ratio and $113.6M cash
- Positive revenue growth of 48% YoY demonstrates commercial traction
- Low leverage (0.00x debt-to-equity) provides financial flexibility
Risks
- Severe cash burn of -$118.9M operating cash flow vs. $20.7M revenue creates ~1 year runway
- Operating losses of -$110M on minimal revenue indicate far from profitability inflection
- Negative and worsening EPS (-$1.69, -161.2% YoY) signals deteriorating financial performance
- High R&D and development costs suggest significant additional capital may be required
- Small revenue base suggests limited approved products or early commercialization phase with execution risk
Key Metrics to Watch
- Quarterly revenue growth rate and gross margin improvement
- Operating cash flow trajectory and path to positive cash generation
- Cash and equivalents balance and estimated runway to profitability
- Pipeline advancement and clinical trial progress for key programs
- Operating expense trends and efficiency improvements
Financial Metrics
Revenue
20.7M
Net Income
-99.1M
EPS (Diluted)
$-1.69
Free Cash Flow
-119.7M
Total Assets
1.2B
Cash
113.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-530.3%
Net Margin
-477.7%
ROE
-8.9%
ROA
-8.4%
FCF Margin
-576.9%
Balance Sheet & Liquidity
Current Ratio
14.19x
Quick Ratio
13.59x
Debt/Equity
0.00x
Debt/Assets
6.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T14:16:41.730061 |
Data as of: 2026-03-31 |
Powered by Claude AI